Biotechnology Patenting: Validity and Infringement - October 21st, 2003
Maximising value: How far can we reach through in patent claims and licensing?
October 21st, 2003 - Brabanthal, Leuven (Belgium)
This one day comprehensive program has been specially designed to offer the latest patent office and practitioner insights in the current standards of biotech patenting and the best research strategies, offensive moves and defensive plays to get maximum value from biotech inventions. The speakers will highlight on genomics, proteonomics, bioinformatics and pharmaceutical patenting.
This seminar is an organisation of Leuven.Inc, in co-operation with K.U.Leuven Research&Development and supported by CIR (Centre for Intellectual Property Rights).
The lectures of this seminar will be in english.
Who should attend?
- Industrial and academical biotech researchers
- Business development, licensing, technology assessment, external collaboration, legal and alliance managers
- Executives and members of the investment community involved in value driven biotechnology projects
- All individuals who want to improve and broaden their knowledge on patent protection, enforcement and freedom to operate
- Patent attorneys, officers and co-ordinators, licensing and intellectual property lawyers, who are involved in protecting and enforcing biotech inventions
Programme
A more detailed programme with abstracts on the lectures and the conference speakers can be downloaded by clicking this link.
09h15 Registration and coffee
09u45 Welcome and introduction - Survey on academical biotechnology patenting
(Koenraad Debackere, Managing Director, K.U.Leuven R&D)
10h00 Opening of the seminar, chaired by
(Geertrui Van Overwalle, Professor, Centre for Intellectual Property Rights, K.U.Leuven)
Session 1: Scope of protection and enforceability of Biotechnology inventions
10h10 The problem universities face with claiming early stage biotechnology inventions
(Ivo Roelants, IPR Officer, K.U.Leuven R&D)
10h40 US & UK perspective / claims scope, validity and infringement in US & UK
(Evan M. Kent, Partner in charge of Transactional Intellectual Property at Mitchell, Silberberg & Knupp, Los Angeles)
11h25 Coffee break
11h40 EPO perspective / claims scope, validity and infringement; Gene patenting
(William Bird, Patent Attorney, Bird Goën & Co)
12h20 Views from the EPO on patentability of receptors and screening methods
(Berthold Rutz, Patent Examiner Biotechnology, European Patent Office, Munich)
13h00 Sandwich lunch
14h00 Reach-Through Claims - Patentability and Dependency - An Industry Perspective
(Allen Norris, Head of the Intellectual Property Department of UCB SA)
Session 2: Research exemptions and technology transfer
14h45 Research exemptions: US & UK perspectives: Latest cases
(Evan M. Kent, Partner in charge of Transactional Intellectual Property at Mitchell, Silberberg & Knupp, Los Angeles)
15h15 Research exemptions: European perspective: German & Belgian situation
(William Bird, Patent Attorney, Bird Goën & Co)
15h45 Coffee break
16h00 Material Transfer Agreements & claims on intellectual property transfer. How far can they go?
(Bruno Lambrecht, Legal Counsel, K.U.Leuven R&D)
16h30 Patent and biomaterial licensing: Research tools, targets and leads
(Olivier Lescroart, Technology Transfer Officer, K.U.Leuven R&D)
17h00 Questions and Answers
17h30 Reception
Information and Registration
Date: October 21, 2003 (9h15-18h30)
Location: Brabanthal, Leuven
Route description: www.brabanthal.be